Neuroprotective effects of D-AlaGIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model by unknown
RESEARCH Open Access
Neuroprotective effects of D-Ala2GIP on
Alzheimer’s disease biomarkers in an APP/PS1
mouse model
Emilie Faivre and Christian Hölscher*
Abstract
Introduction: Type 2 diabetes mellitus has been identified as a risk factor for Alzheimer’s disease (AD).
An impairment of insulin signaling as well as a desensitization of its receptor has been found in AD brains.
Glucose-dependent insulinotropic polypeptide (GIP) normalises insulin signaling by facilitating insulin release.
GIP directly modulates neurotransmitter release, LTP formation, and protects synapses from the detrimental effects
of beta-amyloid fragments on LTP formation, and cell proliferation of progenitor cells in the dentate gyrus. Here
we investigate the potential therapeutic property of the new long lasting incretin hormone analogue D-Ala2GIP on
key symptoms found in a mouse model of Alzheimer’ disease (APPswe/PS1detaE9).
Methods: D-Ala2GIP was injected for 21 days at 25 nmol/kg ip once daily in APP/PS1 male mice and wild type
(WT) littermates aged 6 or 12 months of age. Amyloid plaque load, inflammation biomarkers, synaptic plasticity in
the brain (LTP), and memory were measured.
Results: D-Ala2GIP improved memory in WT mice and rescued the cognitive decline of 12 months old APP/PS1
mice in two different memory tasks. Furthermore, deterioration of synaptic function in the dentate gyrus and
cortex was prevented in 12 months old APP/PS1 mice. D-Ala2GIP facilitated synaptic plasticity in APP/PS1 and WT
mice and reduced the number of amyloid plaques in the cortex of D-Ala2GIP injected APP/PS1 mice. The
inflammatory response in microglia was also reduced.
Conclusion: The results demonstrate that D-Ala2GIP has neuroprotective properties on key hallmarks found in AD.
This finding shows that novel GIP analogues have the potential as a novel therapeutic for AD.
Introduction
Alzheimer’s disease (AD), the most common type of
dementia, is a devastating neurodegenerative disorder
that has an increasingly high incidence in the elderly. At
present, no treatment for AD is known. The disease is
officially characterized by two principle hallmarks of
pathology, which are amyloid plaques and neurofibrillary
tangles (NFTs), composed of aggregated b-amyloid pep-
tide and hyperphosphorylated tau respectively [1-5]. The
most prominent feature of AD is the clinical decline in
cognitive function, with an early impairment of episodic
memory that later manifest as mild cognitive impairment
and then later as AD dementia [6,7]. Other biomarkers
include inflammation of the brain, loss of cholinergic
neurons in the basal brain, glutamatergic neuronal loss,
dendritic and synaptic loss among others [8,9].
Similarities between AD and Type 2 diabetes have been
discovered in the last decades, and increased detailed
knowledge of common physiological processes open up
the opportunities for developing new treatments that
may prevent or reduce the onset of AD [10,11]. Impor-
tantly, the disturbance in insulin signaling appears to be
the main common impairment in both diseases [12-15].
Type 2 diabetes mellitus is characterized by resistance to
insulin. A desensitisation of the insulin receptor has been
also discovered in the brain of AD patients [13,16,17]. In
addition, there is evidence to suggest that beta-amyloid
oligomers bind to insulin receptors in the brain and
cause a reduction of insulin receptor expression on den-
drites [18,19]. This impairment in insulin signaling leads
* Correspondence: c.holscher@ulster.ac.uk
School of Biomedical Sciences, Ulster University, Cromore road, Coleraine,
BT52 1SA, UK
Faivre and Hölscher Alzheimer’s Research & Therapy 2013, 5:20
http://alzres.com/content/5/2/20
© 2013 Faivre et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
to an impairment of neuronal function, plaque formation
and may lead to formation of NFTs [20-22]. This loss of
insulin signaling in the brain may be one of the underly-
ing mechanisms of neurodegeneration in AD. Insulin is a
potent anabolic hormone, and activation of insulin recep-
tor (IR) is essential for cell development, growth, and
repair [23,24]. The IR is widely expressed in the brain
[25] and its activation induces neuronal stem activation
and dendritic sprouting [26,27]. Moreover, insulin plays a
role in neuronal development, neuroprotection and
memory [24,28]. Importantly, insulin can regulate levels
of phosphorylated tau and is a potent neuroprotective
factor, which can increase neuronal survival and protect
neurons against the toxicity of amyloid fragments [29,30].
Since insulin signaling is desensitized in AD and since
it is not sensible to give insulin administration to people
as it would expedite the de-sensitisation in the long run,
alternative strategies are investigated. Glucose-dependent
insulinotropic polypeptide (GIP) is a potential candidate
as it activates a parallel signaling pathway to insulin,
namely, the incretin signaling pathway. GIP is an endo-
genous 42 amino acid peptide hormone, which is released
by intestinal K-cells after a meal [31]. GIP analogues have
been developed as potential treatments for type 2 dia-
betes, and ameliorate impaired insulin release from the
pancreas and facilitate the normalisation of insulin sig-
naling and hyperglycaemia [32,33]. The GIP receptor
(GIPR) is expressed in various tissues and has been found
in several brain regions with high levels of expression in
the olfactory bulb and in the large pyramidal neurons in
the hippocampus and cerebral cortex [34,35]. Activation
of the GIPR leads to proliferation of neuronal progenitor
cells and therefore may contribute to neurogenesis
[35,36]. Moreover, GIP has neuroprotective and regen-
erative properties [37]. GIP prevents the detrimental
effects of beta-amyloid on synaptic plasticity [38] and in
spatial learning and memory during the water maze task
[39]. Furthermore, GIP has been shown to promote axo-
nal regeneration after sciatic nerve injury [40]. However,
as GIP is quickly degraded by the enzyme dipeptidyl
peptidase IV (DPP-IV) [41], several enzyme-resistant
super-GIP molecules have been designed, such as the
D-Ala2GIP [33,42]. Chronic injection of D-Ala2GIP for
21 days enhanced memory formation, synaptic neuro-
transmission (LTP) in the hippocampus, and progenitor
cell proliferation in the dentate gyrus of wild type (WT)
mice without inducing adverse side effects [43]. Addi-
tionally, a recent study has also shown protective effects
of DAla2GIP on synaptic neurotransmission (LTP) and
on object recognition memory when administrated twice
daily over a 28-day period in mice on a high-fat diet [44].
Based on this information, we studied the effect of
chronic systemic administration of D-Ala2GIP in an
APP/PS1 mouse model of AD at different ages. Memory
tasks and in vivo electrophysiology were used to evaluate
potential effects of this GIP analogue on learning, mem-
ory and synaptic plasticity. Immunohistochemical stain-
ing was performed to assess the effects of D-Ala2GIP on
cell proliferation, neurogenesis, synaptic density and on
histological markers (amyloid plaques, dense-core pla-
ques and neuroinflammation) of AD in APP/PS1 mice
[45]. It is hoped that GIP analogues could prevent the
detrimental effects of beta-amyloid on neuronal trans-
mission and learning abilities at the very early stage of
disease, and might reduce the number of plaques found
in the brain in AD, and promote neuronal regeneration
at later stages of the disease.
Materials and methods
Animals
Heterozygous male APPswe/PS1dE9 (APP/PS1) mice
with a C57Bl/6J background were bought from Harlan
(UK) and were bred at the University of Ulster with
wild-type C57Bl/6J females also from Harlan (UK). The
background and generation of APP/PS1 mice used in
this study has been previously described in [46]. From
the offspring, only male APP/PS1 mice, heterozygous
for the APPswe/PS1dE9 transgenic construct, were used
for the experiments, as well as age-matched non-AD
mice, which are WT littermates, as control. Identifica-
tion of the APP/PS1 transgenic and non-transgenic mice
was performed according to the results of the PCR with
primers specific for the APP sequence of the APP/PS1
construct, as outlined in [36]. Once mice were allocated
to the APP/PS1 or control group, they were individually
caged and received food and water ad libitum. Animals
were maintained on a 12/12 light-dark cycle (lights on
at 0800 h, off at 2000 h), in a temperature-controlled
room (21.5°C ± 1). Every test was conducted during the
light cycle. All experiments were licensed according to
UK Home Office regulations (UK Animals Scientific
Procedures Act 1986) and EU laws.
Peptides
D-Ala2GIP was purchased from GL Biochem Ltd
(Shanghai). The purity of the peptide was analysed by
reversed-phase high performance liquid chromatography
(HPLC) and characterised using matrix-assisted laser
desorption/ionisation time of flight (MALDI-TOF) mass
spectrometry.
Drug treatment
Animals were tested at two different ages, 6 months and
12 months. At these ages, APP/PS1 and WT mice were
injected intraperitoneally (ip) at a volume of 10 ml/kg with
saline solution (0.9% NaCl) or D-Ala2GIP at 25 nmol/kg
body weight once daily for 21 days prior to the start of the
behavioural study, and the injections were carried out
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until the end of the experimental study (see Figure 1).
Thus, mice were allocated to four different treatment
groups: saline-treated WT group, D-Ala2GIP-treated WT
group, saline-treated APP/PS1 group and D-Ala2GIP-trea-
ted APP/PS1 group (see Table 1).
Behavioural tasks
Object recognition task (ORT)
The apparatus consisted of an open-field arena (58 cm
in diameter; 31 cm-high walls) constructed in alumi-
nium with painted grey walls and grey floor. The open
field was dimly illuminated by a 60-w lamp placed 2 m
directly above the arena. The objects were red cubes
(1.8 cm wide) and white balls (2.6 cm). The arena and
objects were cleaned with 70% ethanol after each mouse
Figure 1 Events sequence of the experimental procedure for (A) the 6-month-old groups, (B) the 12-month-old group. Mice were
injected for 21 days prior to different behavioural tasks, such as Morris water maze (MWM) task, open-field task and object recognition task
(ORT). Injections were carried out until electrophysiological recordings or perfusions were performed. Arrows correspond to blood collection.
Table 1 Numbers of animals used for analysis of
behavioural tasks and of electrophysiological recording
of fEPSPs, depending on age, genotype and treatment
given
Age Genotype Treatment Behaviour Electrophysiology
6 months WT Saline N = 14 N = 6
6 months WT D-Ala2GIP N = 14 N = 6
6 months APP/PS1 Saline N = 12 N = 8
6 months APP/PS1 D-Ala2GIP N = 12 N = 8
12 months WT Saline N = 11 N = 7
12 months WT D-Ala2GIP N = 12 N = 7
12 months APP/PS1 Saline N = 11 N = 7
12 months APP/PS1 D-Ala2GIP N = 11 N = 6
fEPSP, field excitatory post-synaptic potential; GIP, glucose-dependent
insulinotropic polypeptide; N, number.
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trial to prevent the build-up of olfactory cues. Mice
received a session of 5 minutes in the empty open field
to habituate them to the apparatus and test room. The
mouse was placed in the middle of the open field and
was free to explore it. During that time, motor activity
was recorded by total path, number of lines on the floor
crossed and speed. The number of rearing events (fore-
paws elevated from the floor) was analysed as index of
exploratory behaviour. The anxiety level was assessed by
the percentage of time spent in the centre versus per-
iphery of the arena and the number of grooming ses-
sions. Grooming was defined as behaviour when the
mouse stopped running and start licking, chewing and
scratching at its fur. Twenty four hours after the habi-
tuation each mouse was subjected to a 10-minute acqui-
sition trial, during which they were placed in the open
field in the presence of object A, the first of two non-
identical objects (a cube or a ball), situated 15 cm from
the arena wall (acquisition task). On completion of
10 minutes exploration, the mouse was returned to its
cage for a 3-h delay. After the retention interval, the
mice were placed back into the box and exposed to the
familiar object (A) and to a novel object (B) for a further
10 minutes (test task). The objects were placed in the
same locations as the previous ones. The position of the
novel object was fully counterbalanced (half left, half right)
in a random manner to avoid preferences not based on
novelty. Locomotor activity (number of lines crossed),
speeds (cm/s), travel path and the total time spent explor-
ing each of the two objects (when the animal’s snout was
directly toward the object at a distance ≤ 2 cm), were
recorded. A recognition index was defined as the amount
of time exploring the familiar object or the novel object
over the total time spent exploring both objects, times
100, was used to measure recognition memory: (TA or
TB/(TA + TB))*100. In the acquisition and retention trial,
if the exploration time was < 30 s and < 15 s respectively,
the mice were excluded from the trial. A video camera
was fixed 2 m above the centre point of the arena and was
attached to a video recorder, monitor and computer. The
movement of the animals in the open field was tracked
using a computerized tracking system (Biosignals,
New York).
Morris water maze (MWM) task
The maze was made of white opaque plastic with a dia-
meter of 120 cm and 40 cm-high walls, and was filled
with water at 25°C to avoid hypothermia. A small escape
platform (10 × 6.5 × 21.5 cm) was placed at a fixed posi-
tion in the centre of one quadrant, 25 cm from the peri-
meter, and was hidden 1 cm beneath the water surface.
The room contained a number of fixed visual cues on the
walls. Four points equally spaced along the circumference
of the pool (north, south, east, west) served as the start-
ing position, which was randomised across the four trials
each day. If an animal did not reach the platform within
90 s, it was guided to the platform where it had to remain
for 30 s, before being returned to its home cage. The path
length and escape latencies were recorded. One day after
finishing the acquisition task, a probe trial was performed
to assess the spatial memory (after a 24 h delay). The
platform was removed from the maze and animals were
allowed to swim freely for 60 s.
Surgery and long-term potentiation recording in the
hippocampus, area CA1
The technique used for testing long-term potentiation
(LTP) in the hippocampus was exactly as previously
described [46]. Mice were anaesthetised with urethane
(ethyl carbamate, 1.8 g/kg, ip) for the duration of all
experiments. Electrodes (tungsten with Teflon coating,
Bilaney, UK) were implanted at the following coordinates:
1.5 mm posterior and 1.0 mm lateral for the recording
electrode, and 2.0 mm posterior to bregma and 1.5 mm
lateral to the midline for the stimulating electrode. The
electrodes were lowered through the cortex and the
upper layers of the hippocampus and into the CA1 region
until the appearance of a negative deflecting excitatory
post-synaptic potential (EPSP) that had a latency of ca.10
ms field (f)EPSPs were recorded on a computerised sti-
mulating and recording unit (PowerLab, ADI instru-
ments, USA). The program activated a constant current
stimulus isolation unit (Neurolog, UK). Two different sti-
mulation protocols were used: a weak high-frequency sti-
mulation (HFS) protocol and a strong HFS protocol.
Once fEPSP was found, different stimulation strengths
were applied from 2.0 to 4.5 V in order to record later
basic synaptic transmission. The stimulation strength,
which triggered 50% of the maximum fEPSP response,
was used for all further recordings for the weak HFS pro-
tocol, while the strong HFS protocol used a stimulation
strength set at 75% of the maximum fEPSP response.
This weak protocol was used in order to assess if peptides
could facilitate LTP, as the control group was not poten-
tiated at a maximal rate [38,47]. The stronger high fre-
quency stimulation protocol consisted of three trains of
200 stimuli, inter-train interval 1 s, inter-stimulus inter-
val 5 ms (200 Hz), with the stimulation strength set at
75% of the maximum fEPSP response. LTP was measured
as percent of baseline fEPSP. This strong HFS protocol
was found to potentiate LTP at a higher level under these
stimulation conditions.
Immunohistochemistry
For BrdU staining, mice received a single dose of BrdU
(Sigma-Aldrich, St Louis, Mo, USA; Cat. No. B5002),
50 mg/kg of body weight at a concentration of 10 mg/ml.
Ip injections were done 24 h before perfusion of the mouse
brain.
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After the LTP studies, animals were perfused transcar-
dially with PBS followed by cold 4% paraformaldehyde
in PBS. Brains were removed and fixed in 4% parafor-
maldehyde for at least 24 h before being transferred to
30% sucrose solution overnight. Brains were then snap-
frozen using Envirofreez™ and coronal sections of
40-micron thickness were cut at a depth of -2 to -3
Bregma using a Leica cryostat. Sections were chosen
according to stereological rules [48] with the first sec-
tion taken at random and every fifth section afterwards.
Between seven and thirteen sections were analysed per
brain.
Immunohistochemistry was carried out for the ionized
calcium binding adaptor molecule 1 (Iba1), a marker for
activated microglia to measure the inflammation
response [49], beta-amyloid plaques, congophilic plaques
and doublecortin (DCX), a marker for immature neurons.
All sections were incubated in 3% H2O2 to quench endo-
genous peroxidase activity. For Iba1 immunoreactivity,
sections were incubated in 0.05 M Trisodium citrate (pH
9) at 90°C for 30 minutes to enhance antigen recognition.
After blocking the sections in 5% normal serum to avoid
non-specific antibody binding, they were incubated with
rabbit polyclonal anti-Iba1 (1:2000, Wako, Germany,
016-20001) or goat polyclonal anti-DCX (1:200, Santa
Cruz, CA, USA, sc-710), or polyclonal rabbit anti-synap-
tophysin primary antibody (Abcam, Cambridge, UK; Cat.
No. ab7837), or a monoclonal mouse anti-BrdU antibody
(Sigma-Aldrich, St Louis, Mo, USA; Cat. No. B2531), or
rabbit polyclonal anti amyloid beta peptide (1:250, Invi-
trogen, UK, 71-5800) was added and incubated overnight
at 4°C. For visualisation, Vectastain Elite and SG sub-
strate (Vector laboratories, Burlingame, CA, USA) were
used. Congo red staining for congophilic plaques was
carried out as described by [50]. All staining was visua-
lized by Axio Scope 1 (Zeiss, Germany) and analyzed
using the multi threshold plug-in with Image J (NIH,
USA). The background stain was subtracted in each his-
tology analysis. As controls, sections without the primary
antibody were used to evaluate the non-specific back-
ground stain.
Determination of glucose levels
A few drops of blood were taken from the cut tip of the tail
vein of mice. Blood glucose was measured instantly by an
automated glucose oxidase procedure using the Ascencia®
Contour® Blood Glucose Meter with corresponding analy-
sis strips (Bayer Healthcare, Berkshire, UK).
Determination of insulin levels by radioimmunoassay
Blood samples were collected from the cut tip of the tail
vein of mice into microvette CB300 tubes (Sarstedt,
Numbrecht, Germany; Cat. No. 16.446). Blood samples
were then immediately centrifuged using a refrigerated
centrifuge (Centrifuge 5415 R, Eppendorf AG, Hamburg,
Germany) for 5 minutes at 12,000 × g. The supernatant
plasma was aliquoted and stored at -80°C prior to insu-
lin level determination.
Plasma insulin was assessed by radioimmunoassay
(RIA). At least 24 h prior to use, a stock Dextran-coated
charcoal (DCC) solution was also made up of 5% dex-
tran T70-coated charcoal in stock RIA buffer. For each
sample, 100 μl of guinea pig anti-porcine insulin anti-
serum and 100 μl of I125 bovine insulin (10,000 cpm)
were added. Samples were incubated with 1 ml of DCC
for 20 minutes at 4°C, and then centrifuged at 900 × g
for 20 minutes at 4°C. The resulting supernatant was
gently removed and radioactivity in the charcoal, corre-
sponding to unbound I125 bovine insulin, was measured
using an LKB Wallace gamma counter.
Statistics
Statistical analyses were performed using Prism (Graph-
pad software Inc., USA) with the level of probability set
at 95%. Standard error of the mean is shown in the fig-
ures. Data from the open field and immunostaining were
analysed by one-way analysis of variance (ANOVA), fol-
lowed by the Bonferroni post hoc test when the P-value
was < 0.05, to measure the difference between groups.
Student’s paired t-test was used for the ORT and object
location test (OLT) when the time spent exploring the
familiar object/location was compared to the time spent
exploring the novel object/location. Two-way repeated
measures ANOVA was used to analyse differences
between groups, effects over time and interactions for
every behavioural measure (path length, escape latency
and swim speed) of the acquisition task and to determine
the difference in time spent between quadrants for each
group in the probe trial, followed by the Bonferroni post
hoc test. To evaluate difference in synaptic activity
between groups, two-way repeated measures ANOVA
was performed for the post-HFS baseline with group as
independent variable and time as dependent variable.
The same analysis was performed for the pre-HFS base-
line to assess difference between groups over time.
Results
Body weights
Analysis at 6 months
On two-way ANOVA of mice at 6 months of age, there
was an overall difference between groups (F = 14.20, P <
0.0001) but no difference over time (F = 2.07, P > 0.05),
and there was no interaction of the two factors (F = 0.07,
P > 0.05). Then, the body weight of WT mice injected
with saline was compared with that of WT mice injected
with D-Ala2GIP. On two-way ANOVA, there was no dif-
ference between groups (F = 2.77, P > 0.05), no effect
over time (F = 0.91, P > 0.05) and no interaction of the
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two variables (F = 0.02, P > 0.05). The same analysis was
performed comparing the body weight of APP/PS1 mice
injected with saline and the body weight of APP/PS1
mice injected with D-Ala2GIP. On two-way ANOVA
there was no difference between groups (F = 1.27, P >
0.05), no effect over time (F = 0.0004, P > 0.05) and no
interaction of the two variables (F = 0.03, P > 0.05). How-
ever, there was a difference in body weight between WT
and APP/PS1 mice that were both injected with saline
(F = 12.47, P < 0.0001), as well as between WT and APP/
PS1 mice that were both injected with D-Ala2GIP (F =
30.40, P < 0.0001). No difference was found over time in
the saline groups (F = 0.82, P > 0.05) and D-Ala2GIP
groups (F = 1.32, P > 0.05). No effect of interaction of
both group and time was shown between the saline
groups (F = 0.03, P > 0.05), or between the D-Ala2GIP
groups (F = 0.19, P > 0.05). These statistics show that
APP/PS1 mice had a higher body weight compared to
WT control mice, which was not influenced by the saline
or D-Ala2GIP injection (Figure 2A).
Analysis at 12 months
On two-way ANOVA of mice at 12 months of age there
was an overall difference between groups (F = 16.85,
P < 0.0001) and over time (F = 7.11, P < 0.0001), but no
interaction of the two factors (F = 0.10, P > 0.05). Then,
the body weight of WT mice injected with saline was
compared with the body weight of WT mice injected
with D-Ala2GIP. On two-way ANOVA there was a
slight difference between groups (F = 6.25, P < 0.05),
with an effect over time (F = 5.60, P < 0.0001), but
Figure 2 Weight of APP/PS1 mice and their age-matched wild type control mice. Mice were injected with saline and D-Ala2 glucose-
dependent insulinotropic polypeptide (GIP) at 6 months of age. Mice were weighed one day before injections started and every 5 days over a
period of 30 days. (A) Body weight at 6 months. Data represent mean ± standard error of the mean (SEM) of 14 wild type (WT) mice per group
and 12 APP/PS1 mice per group (two-way analysis of variance, ANOVA). (B) Body weight at 12 months. Data represent mean ± SEM of 11 WT
mice injected with saline, 12 WT mice injected with D-Ala2GIP and 11 APP/PS1 per group (two-way ANOVA).
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there was no interaction of the two variables (F = 0.09,
P > 0.05). The same analysis was performed comparing
the body weight of APP/PS1 mice injected with saline
and the body weight of APP/PS1 mice injected with D-
Ala2GIP. There was no difference between groups (F =
1.08, P > 0.05), and no effect of interaction of the two
variables (F = 0.06, P > 0.05), but a slight effect of time
was found (F = 2.70, P < 0.05). On two-way ANOVA
there was a difference in body weight between WT and
APP/PS1 mice that were both mice injected with saline
(F = 26.79, P < 0.0001) over time (F = 4.79, P < 0.0001),
as well as between WT and APP/PS1 mice that were
both injected with D-Ala2GIP (F = 21.08, P < 0.0001)
with a slight effect of time (F = 2.88, P < 0.05). No effect
of interaction of groups and time was shown between
the saline groups (F = 0.27, P > 0.05) or between the D-
Ala2GIP groups (F = 0.05, P > 0.05). These statistics
show that APP/PS1 mice had a higher body weight
compared to WT control mice, and the D-Ala2GIP
peptide slightly decreased the body weight when injected
in WT mice. Moreover a decrease in body weight was
observed over time for all groups (Figure 2B).
Blood glucose and plasma insulin levels
Analysis at 6 months
On two-way repeated measures ANOVA in mice at 6
months of age, there was a difference between groups in
glucose concentrations (F = 4.08, P < 0.01), and over
time (F = 7.23, P < 0.0001), and an influence of interac-
tion between the two factors (F = 3.6, P < 0.0001)
(Figure 3A). Bonferroni post hoc analysis revealed a sig-
nificant increase in glucose concentrations in APP/PS1
mice injected with saline compared to WT mice injected
with saline (P < 0.01) on day 34. Moreover, injection of
D-Ala2GIP for 34 days increased blood glucose levels of
APP/PS1 mice compared to WT mice (P < 0.0001).
However, blood glucose levels stayed in a normal range
(between 4 and 8 mM/l) for all groups over time.
Figure 3 Determination of (A) blood glucose levels, (B) plasma insulin levels in APP/PS1 mice and their age-matched wild type control
mice, injected with saline or D-Ala2 glucose-dependent insulinotropic polypeptide (GIP) at 6 months old, and (C) blood glucose levels
and (D) plasma insulin levels at 12 months. Data represent mean ± standard error of the mean (SEM) of 14 wild type (WT) mice per group
and 12 APP/PS1 mice per group (two-way analysis of variance, ANOVA, *P < 0.05; ** P < 0.01). (C, D) Data represent mean ± SEM of 11 WT mice
injected with saline, 12 WT mice injected with D-Ala2GIP and 11 APP/PS1 per group (two-way ANOVA, *P < 0.05).
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On two-way repeated measures ANOVA there was no
difference between groups in plasma insulin levels (F =
1.75, P > 0.05), no difference over time (F = 1.91, P >
0.05), and no effect of interaction between the two fac-
tors (F = 0.96, P > 0.05) (Figure 3B).
Analysis at 12 months
On two way repeated measures ANOVA of mice at 12
months of age there was a slight difference between
groups in glucose concentrations (F = 3.84, P < 0.05),
and a difference over time (F = 7.14, P < 0.0001), which
was not influenced by interaction between the two fac-
tors (F = 1.39, P > 0.05) (Figure 3C). Bonferroni post
hoc analyses revealed a significant decrease of glucose
concentrations in APP/PS1 mice injected with saline
compared to WT mice injected with saline (P < 0.05)
on day 21 and 36. However, blood glucose levels stayed
in the normal range (between 4 and 8 mM/l) for all
groups over time. On two-way repeated measures
ANOVA there was no difference between groups in
plasma insulin levels (F = 1.56, P > 0.05), no difference
over time (F = 0.74, P > 0.05) and no effect of interaction
for the two factors (F = 0.54, Pp > 0.05) (Figure 3D).
Effect of D-Ala2GIP treatment on spontaneous behaviour
of APP/PS1 mice and WT littermates
Analysis at 6 months
In the open-field task at 6 months of age, the sponta-
neous behaviour of WT and APP/PS1 mice injected
with saline or D-Ala2GIP was similar. On one-way
ANOVA there was no difference between groups in
path length (F = 1.99, P > 0.05), number of lines crossed
(F = 1.59, P > 0.05), speed (F = 1.99, P > 0.05), explora-
tion levels (F = 0.29, P > 0.05), grooming events (F =
0.85, P > 0.05), or the ratio of time spent in the centre
of the arena to the periphery (F = 1.29, P > 0.05) (data
not shown).
Analysis at 12 months
In the open-field task at 12 months of age, the sponta-
neous behaviour of WT and APP/PS1 mice injected
with saline or D-Ala2GIP was similar. On one-way
ANOVA there was no difference between groups in
path length (F = 1.14, P > 0.05), number of lines crossed
(F = 0.94, P > 0.05), speed (F = 1.14, P > 0.05), explora-
tion levels (F = 0.56, P > 0.05, grooming events (F =
0.21, P > 0.05), and the ratio of time spend in the centre
of the arena to the periphery (F = 0.07, P > 0.05) (data
not shown).
Effect of D-Ala2GIP treatment on object recognition
memory of APP/PS1 mice and WT littermates
Analysis at 6 months
In the test trial, there was a difference (Student’s paired
t-test) in the recognition index (RI) of novel vs familiar
objects for WT mice injected with saline (t = 2.28, P <
0.05) and with D-Ala2GIP (25 nmol/kg) (t = 2.37, P <
0.05), as well as for APP/PS1 mice injected with saline
(t = 3.71, P < 0.01) and with D-Ala2GIP (t = 2.28, P <
0.05). On one-way ANOVA there was no difference
between groups in the difference in score between the
time spent exploring the novel and the familiar object
(F = 0.27, P > 0.05). These results indicate that all
groups had an intact object recognition memory at
6 months of age (Figure 4).
Analysis at 12 months
In the test trial, there was a difference (Student’s paired
t-test) in the RI of novel vs familiar objects for 12-
month-old WT mice injected with saline (t = 2.07, P <
0.05) and with D-Ala2GIP (25 nmol/kg) (t = 2.51, P <
0.05), showing an intact object recognition memory in
these groups. APP/PS1 mice injected with D-Ala2GIP
spent significantly more time exploring the novel object
than the familiar one (t = 2.80, P < 0.01), while APP/
PS1 control mice injected with saline did not discrimi-
nate between the familiar and the novel task, as no dif-
ference was found in the time spent between them (t =
1.33, P > 0.05), reflecting an impairment in recognition
memory for this group. On one-way ANOVA, there was
no difference between groups in the difference in score
between the time exploring the novel and the familiar
object (F = 1.15, P > 0.05); even the APP/PS1 group
injected with saline solution showed a trend towards
reduction of the difference in score in comparison to
the other groups but this difference was not significant
(Figure 4).
Effect of D-Ala2GIP treatment on spatial learning and
memory of APP/PS1 mice and WT littermates
Analysis at 6 months
During the acquisition task, all mice learned to locate
the hidden escape platform. On two-way repeated mea-
sures ANOVA there was a decrease in escape latency
across trials of training in the acquisition trial (trials:
F = 11.47, P < 0.0001), but there was no difference
between groups (F = 0.64, P > 0.05) and no interaction
of training trials and groups (F = 0.86, P > 0.05).
A decrease in path length was also found across training
trials (F = 13.75, P < 0.0001), although no differences
were detected between groups (F = 0.75, P > 0.05).
There was no interaction of training trials and groups
(F = 0.97, P > 0.05). On two-way repeated measures
ANOVA there was a difference in swim speed over time
(trials: F = 7.01, P < 0.0001) but not between groups
(F = 1.96, P > 0.05). No effect was found for the interac-
tion of both factors (F = 1.19, P > 0.05) (data not
shown).
In the probe trial, on one-way ANOVA there was an
effect of quadrant preference for WT mice injected with
saline (F = 9.70, P < 0.0001), and D-Ala2GIP (F = 7.60,
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Figure 4 Assessment of recognition memory of 6-month-old APP/PS1 mice and wild type age-matched mice injected with saline and
with D-Ala2 glucose-dependent insulinotropic polypeptide (GIP) for 32 days and assessment of recognition memory of 12-month-old
mice injected for 34 days. Recognition index (RI) for familiar and novel locations during the test task (after a 3-h delay). Data represent mean ±
standard error of the mean (SEM) of wild type (WT) mice injected with (A) saline (n = 14) and (B) D-Ala2GIP (n = 14), and APP/PS1 mice injected
with (C) saline (n = 12) and (D) D-Ala2GIP (n = 12), (Student’s paired t-test, *P < 0.05; **P < 0.01). (E) Difference in score of time spent exploring
familiar and novel objects for each group (one-way analysis of variance, ANOVA). At 12 months, WT mice injected with (F) saline (n = 11) and
(G) D-Ala2GIP (n = 11), and APP/PS1 mice injected with (H) saline (n = 11) and (I) D-Ala2GIP (n = 11) (Student’s paired t-test, *P < 0.05; **P <
0.01). (J) Difference in score for time spent exploring familiar and novel objects for each group (one-way ANOVA).
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P < 0.0001), and the APP/PS1 mice injected with saline
(F = 11.83, P < 0.0001) and D-Ala2GIP (F = 6.47, P <
0.01), indicating that all groups remembered the loca-
tion of the escape platform. In the WT saline-injected
group, Bonferroni post hoc analysis showed increased
time of stay in the target quadrant (south-west, S-W)
compared to the south-east (S-E) (P < 0.001), north-east
(N-E) (P < 0.001) and north-west (N-W) (P < 0.01)
quadrants. In the WT D-Ala2GIP-injected group, Bon-
ferroni post hoc analysis showed increased time of stay
in the target quadrant (S-W) compared to the S-E (P <
0.01), N-E (P < 0.01) and N-W (P < 0.001) quadrants.
In the APP/PS1 saline-injected group, Bonferroni post
hoc analyses showed increased time of stay in the target
quadrant (S-W) compared to the S-E (P < 0.05), N-E
(P < 0.001) and N-W (P < 0.05) quadrants. APP/PS1
mice injected with D-Ala2GIP spent more time in the
target S-W quadrant compared to the other (P < 0.01)
(data not shown).
The probe trial was further analysed using one-way
ANOVA, to analyse the difference in time spent in the
target quadrant between all groups. No significant dif-
ference was found between groups for this parameter
(F = 0.37, P > 0.05). Moreover, there was no difference
between groups in the time spent crossing the exact
previous location of the platform (F = 0.50, P > 0.05).
During the reversal task, all mice learned the new
location of the platform. On two-way repeated measures
ANOVA there was a significant decrease in escape
latency across trials of training in the acquisition trial
(trials: F = 5.76, P < 0.0001). A difference in escape
latency was also found between groups (F = 4.97, P <
0.01), which was not influenced by interaction of train-
ing trials and groups (F = 0.83, P > 0.05). Then, on two-
way repeated measures ANOVA to compare the escape
latency between WT injected with saline and those
injected with D-Ala2GIP there was a difference over
time (trials: F = 3.17, P < 0.0001), but not between
groups (F = 2.44, P > 0.05), and there was no effect of
interaction between both factors (F = 0.54, P > 0.05).
The same analysis comparing the APP/PS1 group
injected with saline and that injected with D-Ala2GIP
showed a significant difference between groups in
escape latency (F = 4.36, P < 0.05) and over time (F =
4.00, P < 0.0001), which was not influenced by interac-
tion between factors (F = 0.82, P > 0.05). On two-way
ANOVA there was a difference in escape latency
between WT and APP/PS1 mice that were both injected
with saline (F = 4.85, P < 0.05), as well as between WT
and APP/PS1 mice that were both injected with D-Ala2-
GIP (F = 3.91, P < 0.05). A difference was also found
over time for the saline (F = 2.73, P < 0.01) and D-Ala2-
GIP groups (F = 3.66, P < 0.0001). No effect of
interaction of both group and time was shown between
the saline groups (F = 1.18, P > 0.05), or between the
D-Ala2GIP groups (F = 0.76, P > 0.05).
On two-way repeated measures ANOVA there was a
significant decrease in path length across trials of train-
ing in the acquisition trial (trials: F = 4.28, P < 0.0001).
A difference in escape latency was also found between
groups (F = 6.54, P < 0.0001), which was not influ-
enced by interaction of training trials and groups (F =
0.64, P > 0.05). Then, on two-way repeated measures
ANOVA to compare the escape latency between WT
injected with saline and D-Ala2GIP, there was a differ-
ence over time (trials: F = 16.06, P < 0.0001), but not
between groups (F = 2.58, P > 0.05) and no effect of
interaction between the two factors (F = 3.47, P >
0.05). The same analysis was conducted to compare
the APP/PS1 group injected with saline and that
injected with D-Ala2GIP, and this showed a significant
difference in the escape latency training trials (F =
1.86, P < 0.05), but not between groups (F = 0.63, P >
0.05) and no effect of interaction between factors (F =
0.43, P > 0.05). On two-way ANOVA there was no dif-
ference in escape latency between WT and APP/PS1
mice that were both injected with saline (F = 9.7, P >
0.05), or between WT and APP/PS1 mice that were
both injected with D-Ala2GIP (F = 8.74, P > 0.05). No
difference was found over time for the saline groups (F
= 1.93, P > 0.05) and the D-Ala2GIP groups (F = 2.80,
P > 0.05). No effect of interaction of group and time
was shown between the saline groups (F = 0.95, P >
0.05), or between the D-Ala2GIP groups (F = 0.65, P >
0.05). On two-way repeated measures ANOVA there
was no difference between groups in swim speed over
time, or interaction between the two factors (trials: F =
1.41, P > 0.05; groups: F = 0.61, P > 0.05; interaction:
F = 1.07, P > 0.05).
In the reversal probe trial, on one-way ANOVA there
was an effect of quadrant preference for WT mice
injected with saline (F = 7.67, P < 0.0001), and D-Ala2-
GIP (F = 5.13, P < 0.01), and the APP/PS1 mice injected
with saline (F = 4.76, P < 0.01) and D-Ala2GIP (F =
7.45, P < 0.0001), indicating that all groups remembered
the location of the escape platform. In the WT saline-
injected group, Bonferroni post hoc analysis showed
increased time of stay in the target quadrant (N-W)
compared to the N-E (P < 0.05) and S-E (P < 0.001)
quadrants. In the WT D-Ala2GIP-injected group, Bon-
ferroni post hoc analyses showed increased time of stay
in the target quadrant (N-W) compared to the N-E (P <
0.01) and S-E (P < 0.05) quadrants. In the APP/PS1 sal-
ine-injected group, Bonferroni post hoc analysis showed
increased time of stay in the target quadrant (N-W)
compared to the others (P < 0.05). APP/PS1 mice
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injected with D-Ala2GIP spent more time in the target
S-W quadrant than in the N-E (P < 0.05) and S-E (P <
0.001) and the S-W (P < 0.05) quadrants.
The reversal probe trial was further analysed using
one-way ANOVA, to analyse the difference between all
groups in the time spent in the target quadrant. No sig-
nificant difference was found between groups for this
parameter (F = 0.48, P > 0.05). Additionally, one-way
ANOVA did not show any difference in the spent time
crossing the exact previous location of the platform
between groups (F = 0.83, P > 0.05).
Analysis at 12 months
During the acquisition task, on two-way repeated mea-
sures ANOVA there was a decrease in escape latency
across trials of training in the acquisition trial (trials: F
= 10.20, P < 0.0001), with a difference between groups
(F = 5.92, P < 0.0001), which was not influenced by
interaction of training trials and groups (F = 0.67, P >
0.05). Then, on two-way repeated measures ANOVA to
compare the escape latency between WT injected with
saline D-Ala2GIP we found a difference over time (trials:
F = 4.20, P < 0.0001), and between groups (F = 9.29,
P > 0.005), but no effect of interaction between the two
factors (F = 0.79, P > 0.05). The same analysis between
the APP/PS1 group injected with saline or with D-Ala2-
GIP and showed a significant difference in escape
latency between groups (F = 6.15, P < 0.05) and over
time (F = 6.86, P < 0.0001), which was not influenced
by interaction between factors (F = 0.0.48, P > 0.05). On
two-way ANOVA, there was no difference in escape
latency between WT and APP/PS1 mice that were both
injected with saline (F = 0.42, P > 0.05), as well as
between WT and APP/PS1 mice both injected with D-
Ala2GIP (F = 1.77, P > 0.05). However, a difference was
found over time for the saline groups (F = 3.35, P <
0.0001) and D-Ala2GIP groups (F = 8.14, P < 0.0001).
No effect of interaction of group and time was shown
between the saline groups (F = 0.69, P > 0.05), or
between the D-Ala2GIP groups (F = 0.45, P > 0.05).
A decrease in path length was also found across train-
ing trials (F = 17.60, P < 0.0001), and differences were
detected between groups (F = 6.043, P < 0.0001). There
was no interaction of training trials and groups (F =
0.73, P > 0.05). Then, on two-way repeated measures
ANOVA to compare the path length between WT
injected with saline or D-Ala2GIP there was a difference
over time (trials: F = 8.48, P < 0.0001), but not between
groups (F = 0.01, P < 0.05), and no effect of interaction
between the two factors was detected (F = 0.96, P >
0.05). The same analysis between the APP/PS1 group
injected with saline or D-Ala2GIP showed a significant
difference in escape latency over trials (F = 9.60, P <
0.0001), but not between groups (F = 61.36, P > 0.05),
and there was no effect of interaction between factors
(F = 0.47, P > 0.05). On two-way ANOVA there was a
difference in escape latency between WT and APP/PS1
mice that were both mice injected with saline (F = 4.99,
P < 0.05), as well as between WT and APP/PS1 mice
both injected with D-Ala2GIP (F = 1.77, P > 0.05).
A difference was found over time for the saline groups
(F = 9.12, P < 0.0001) and D-Ala2GIP groups (F = 9.28,
P < 0.0001). No effect of interaction of group and time
was shown between the saline groups (F = 0.88, P >
0.05), or between the D-Ala2GIP groups (F = 0.60, P >
0.05). On two-way repeated measures ANOVA there
was a difference in swim speed over time (trials: F =
7.49, P < 0.0001) but not between groups (F = 2.30, P >
0.05). No effect was found for the interaction of the two
factors (F = 0.55, P > 0.05) (data not shown).
In the probe trial, one-way ANOVA showed an effect
of quadrant preference for WT mice injected with saline
(F = 3.02, P < 0.05) or D-Ala2GIP (F = 12.06, P <
0.0001), and the APP/PS1 mice injected with D-Ala2GIP
(F = 7.47, P < 0.0001). However, APP/PS1 mice injected
with saline spent an equal amount of time in each quad-
rant of the pool (F = 0.16, P > 0.05), indicating that this
group did not remember the location of the escape plat-
form. In the WT saline-injected group, Bonferroni post
hoc analysis showed increased time of stay in the target
quadrant (S-W) compared to the N-W (P < 0.05) quad-
rant. In the WT D-Ala2GIP-injected group, Bonferroni
post hoc analyses showed increased time of stay in the
target quadrant (S-W) compared to the other quadrants
(P < 0.001). In the APP/PS1 D-Ala2GIP-injected group,
Bonferroni post hoc analyses showed increased time of
stay in the target quadrant (S-W) compared to the S-E
(P < 0.05), N-E (P < 0.001) and N-W (P < 0.01) quad-
rants. See Figure 5.
The probe trial was further analysed using one-way
ANOVA of the difference between all groups in the
time spent in the target quadrant (Figure 5). A signifi-
cant difference between groups was found for this para-
meter (F = 3.31, P < 0.05). Bonferroni post hoc analysis
showed a decrease in time spent in the target quadrant
for the APP/PS1 group injected with saline compared to
the WT group injected with D-Ala2GIP (P < 0.05).
Moreover, on one-way ANOVA there was no difference
in the time spent crossing the exact previous location of
the platform between groups (F = 0.87, P > 0.05). How-
ever, the APP/PS1 control group showed a trend
towards a reduction in the time spent in the platform
location compared to the other groups.
During the reversal task, on two-way repeated mea-
sures ANOVA there was a significant decrease in escape
latency across trials of training in the acquisition trial
(trials: F = 4.39, P < 0.0001). A difference in escape
latency was also found between groups (F = 7.69, P <
0.0001), which was not influenced by interaction of
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Figure 5 Evaluation of spatial memory during the probe trial of 12-month-old APP/PS1 mice and wild type age-matched mice
injected with saline or with D-Ala2 glucose-dependent insulinotropic polypeptide (GIP) for 27 days and reversal probe trial of
12-month-old mice injected for 31 days. Time spent in each quadrant of the water maze during the probe trial for wild type (WT) mice
injected with (A) saline and with (B) D-Ala2GIP and APP/PS1 mice injected with (C) saline and with (D) D-Ala2GIP. Data represent mean ±
standard error of the mean (SEM) of 11 WT mice injected with saline, 12 WT mice injected with D-Ala2GIP and 11 APP/PS1 per group. (E) Time
spent in the target quadrant for all groups. (F) Time spent crossing the platform previously located during acquisition task. Data represent mean
± SEM of 11 WT mice injected with saline, 12 WT mice injected with D-Ala2GIP and 11 APP/PS1 per group (one-way analysis of variance,
ANOVA). At 12 months, time spent in each quadrant of the water maze during the probe trial for WT injected with (G) saline and with (H) D-
Ala2GIP and APP/PS1 mice injected with (I) saline and with (J) D-Ala2GIP. Data represent mean ± SEM of 11 WT mice injected with saline, 12 WT
mice injected with D-Ala2GIP and 11 APP/PS1 per group (one-way ANOVA; post hoc test, *P < 0.05; **P < 0.01; ***P < 0.001). (K) Time spent in
the target quadrant for all groups. (L) Time spent crossing the platform previously located during acquisition task (one-way ANOVA, * P < 0.05).
(M) Evaluation of visual acuity of 12-month-old APP/PS1 mice and WT age-matched mice injected with saline or with D-Ala2GIP, during the
visible platform task. Escape latency for the four trials was average for each mouse (one-way ANOVA).
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training trials and groups (F = 0.72, P > 0.05). Then, on
two-way repeated measures ANOVA to compare the
escape latency between WT injected with saline or D-
Ala2GIP, there was a difference over time (trials: F =
3.00, P < 0.0001), and between groups (F = 19.83, P <
0.0001), which was not influenced by interaction
between factors (F = 0.45, P > 0.05). The same analysis
was conducted between the APP/PS1 group injected
with saline or D-Ala2GIP and showed a significant dif-
ference in escape latency between trials (F = 1.19, P <
0.05), but not between groups (F = 3.21, P > 0.05), and
no effect of interaction between both factors was
detected (F = 1.28, P > 0.05). On two-way ANOVA
there was no difference in escape latency between WT
and APP/PS1 mice that were both injected with saline
(F = 1.45, P < 0.05), or over time (F = 1.55, P > 0.05).
Moreover, on two-way ANOVA there was no difference
in escape latency between WT and APP/PS1 mice that
were both injected with D-Ala2GIP (F = 1.56, P > 0.05),
but a difference was found over time (F = 4.87, P <
0.0001). No effect of interaction of group and time was
shown between the saline groups (F = 0.40, P > 0.05), or
between the D-Ala2GIP groups (F = 0.45, P > 0.05).
On two-way repeated measures ANOVA there was a
significant decrease in path length across trials of train-
ing in the acquisition trial (trials: F = 2.79, P < 0.01),
but not between groups (F = 0.99, P > 0.05), and no
effect of interaction of both factors was detected (F =
1.13, P > 0.05). On two-way repeated measures ANOVA
there was no difference between groups in swim speed
over time, or interaction between the two factors (trials:
F = 0.46, P > 0.05; groups: F = 0.84, P > 0.05; interac-
tion: F = 0.91, P > 0.05) (data not shown).
In the reversal probe trial, one-way ANOVA showed an
effect of quadrant preference for WT mice injected with
saline (F = 3.80, P < 0.05), or D-Ala2GIP (F = 5.41, P <
0.01), and the APP/PS1 mice injected with D-Ala2GIP (F
= 7.39, P < 0.0001). However, APP/PS1 mice injected
with saline spent an equal amount of time in each quad-
rant of the pool (F = 02.40, P > 0.05), indicating that this
group did not remember the location of the escape plat-
form. In the WT saline-injected group, Bonferroni post
hoc analyses showed increased time of stay in the S-W
quadrant compared to the N-E (P < 0.05) quadrant, indi-
cating that this group did not remember the location of
the escape platform. In the WT D-Ala2GIP-injected
group, Bonferroni post hoc analyses showed increased
time of stay in the target quadrant (N-W) compared to
the S-E (P < 0.05) quadrant. The APP/PS1 D-Ala2GIP-
injected with D-Ala2GIP spent more time in the target
N-W quadrant compared to the N-E (P < 0.05) and S-E
(P < 0.001) quadrants. See Figure 5b.
The reversal probe trial was further analysed using a
one-way ANOVA of the difference between all groups
in the time spent in the target quadrant (Figure 6).
A significant difference between groups was found for
this parameter (F = 3.27, P < 0.05). Moreover, one-way
ANOVA showed a difference in the time spent crossing
the exact previous location of the platform between
groups (F = 3.42, P < 0.05). Both the WTand APP/
PS1group injected with saline showed a trend towards a
reduction in the time spent in the platform location
compared to the other groups, but the difference was not
significant. In the visible platform task, one-way ANOVA
did not show any difference in escape latency between
groups in visual acuity (F = 0.89, P > 0.05) (Figure 5b).
In summary, the drug treatment did not have any
effects in mice that were 6 months old, at an age when
the amyloid plaque load and the associated learning
impairments had not yet developed. However, D-Ala2-
GIP improved memory in WT mice and rescued the
cognitive decline of 12 month-old APP/PS1 mice in two
different memory tasks.
Effect of D-Ala2GIP treatment on synaptic plasticity of
APP/PS1 mice and WT littermates
Analysis at 6 months
The pre-HFS baselines of WT mice at 6 months of age
were analysed by two-way repeated measures ANOVA
(Figure 6a). No difference was found between the saline
group and D-Ala2GIP group (F = 1.24, P > 0.05), and no
effect of time (F = 0.74, P > 0.05) or interactive effect of
group and time was determined (F = 0.61, P > 0.05), indi-
cating that pre-HFF baselines were stable and similar
between groups over time. On two-way repeated mea-
sures ANOVA there was a clear difference in post-HFS
baselines between the WT group injected with saline and
the WT group injected with D-Ala2GIP (groups: F =
289.3, P < 0.0001), but not over time (F = 0.63, P > 0.05)
and no interactive effect of group and time was found
(interaction: F = 0.93, P > 0.05). Altogether, these results
indicate that HFS stimulation induced robust LTP in the
WT D-Ala2GIP-injected mice compared to the control
group. On two-way repeated measures ANOVA there
was no difference between groups in paired-pulse facilita-
tion (PPF) (F = 0.26, P > 0.05). Inter-stimulus delay (F =
0.57, P > 0.05) and interaction between both factors (F =
1.11, P > 0.05) were not significant.
The pre-HFS baselines of APP/PS1 mice at 6 months of
age were analysed by two-way repeated measures
ANOVA. No difference was found between the saline
and D-Ala2GIP group (F = 0.00007, P > 0.05), and no
effect of time (F = 0.94, P > 0.05) and no interactive effect
of group and time was determined (F = 0.60, P > 0.05),
indicating that pre-HFF baselines were stable and similar
between groups over time. On two-way repeated mea-
sures ANOVA there was a clear difference of post-HFS
baselines between the APP/PS1 group injected with
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Figure 6 In vivo recording of field excitatory postsynaptic potentials (fEPSPs), from the stratum radiatum in response to stimulation of
the Schaffer collateral/commissural pathway in wild type mice, injected with saline and D-Ala2 glucose-dependent insulinotropic
polypeptide (GIP and in APP/PS1 mice. At 6 months, (A) potentiation of the fEPSP after high-frequency stimulation and (B) paired-pulse
facilitation in area CA1. The inter-stimulus interval was set at 25 to 200 ms. Data represent mean ± standard error of the mean (SEM) of six mice
per group (two-way repeated measures analysis of variance, ANOVA). In the APP/PS1 mice, (C) potentiation of the fEPSP after high-frequency
stimulation and (D) paired-pulse facilitation in area CA1. The inter-stimulus interval was set at 25 to 200 ms. Data represent mean ± SEM of eight
mice per group (two-way repeated measures ANOVA). At 12 months, (E) potentiation of the fEPSP after high frequency stimulation and (F)
paired-pulse facilitation in area CA1. The inter-stimulus interval was set at 25 to 200 ms. Data represent mean ± SEM of seven mice per group
(two-way repeated measures ANOVA). In the APP/PS1 mice, (G) potentiation of the fEPSP after high-frequency stimulation and (H) paired-pulse
facilitation in area CA1. The inter-stimulus interval was set at 25 to 200 ms. Data represent mean ± SEM of seven mice for the saline group and
six for the D-Ala2GIP group (two-way repeated measures ANOVA).
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saline and the APP/PS1 group injected with D-Ala2GIP
(groups: F = 309.2, P < 0.0001), but not over time (F =
0.94, P > 0.05) and no interactive effect of group and
time was found (interaction: F = 0.60, P > 0.05). Alto-
gether, these results indicate that HFS stimulation
induced robust LTP in the APP/PS1 D-Ala2GIP-injected
mice compared to the control group. On two-way
repeated measures ANOVA there was a difference
between groups in PPF (F = 4.07, P < 0.05). Inter-stimu-
lus delay (F = 0.69, P > 0.05) and interaction between the
two factors (F = 0.58, P > 0.05) were not significant. See
Figure 6a.
Analysis at 12 months
The pre-HFS baselines of WT mice at 12 months of age
were analysed by two-way repeated measures ANOVA
(Figure 6b). No difference was found between the saline
and D-Ala2GIP group (F = 1.18, P > 0.05), but an effect
of time was determined (F = 2.00, P < 0.01), which was
not influenced by interaction of group and time (F =
0.57, P < 0.01), indicating that pre-HFF baselines were
similar between groups. On two-way repeated measures
ANOVA there was a clear difference of post-HFS base-
lines between the WT group injected with saline and
the WT group injected with D-Ala2GIP (groups: F =
427.0, P < 0.0001), but not over time (F = 1.19, P >
0.05) and no interactive effect of group and time was
found (interaction: F = 0.46, P > 0.05). Altogether these
results indicate that HFS stimulation induced robust
LTP in the WT D-Ala2GIP-injected mice compared to
the control group. On two-way repeated measures
ANOVA there was no difference between groups on
PPF (F = 0.28, P > 0.05). Inter-stimulus delay (F = 1.41,
P > 0.05) and interaction between both factors (F =
0.58, P > 0.05) were not significant.
The pre-HFS baselines of APP/PS1 mice at 12 months
of age were analysed by two-way repeated measures
ANOVA. No difference was found between the saline
and the D-Ala2GIP group (F = 0.00001, P > 0.05), and
no effect of time (F = 1.18, P > 0.05) and no interactive
effect of group and time was determined (F = 1.18, P >
0.05), indicating that pre-HFF baselines were stable and
similar between groups over time. On two-way repeated
measures ANOVA there was a clear difference of post-
HFS baselines between the APP/PS1 group injected with
saline and the APP/PS1 group injected with D-Ala2GIP
(groups: F = 234.1.2, P < 0.0001), but not over time (F =
0.54, P > 0.05) and no interactive effect of group and
time was found (interaction: F = 0.26, P > 0.05). Alto-
gether these results indicate that HFS stimulation
induced robust LTP in the APP/PS1 D-Ala2GIP-injected
mice compared to the control group. On two-way
repeated measures ANOVA there was no difference
between groups on PPF (F = 0.33, P > 0.05). Inter-
stimulus delay (F = 0.39, P > 0.05) and interaction
between the two factors (F = 0.16, P > 0.05) were not
significant. See Figure 6b.
In conclusion, D-Ala2GIP facilitated synaptic plasticity
in APP/PS1 and WT mice at all ages tested.
Effect of D-Ala2GIP treatment on cell proliferation and
neurogenesis of APP/PS1 mice and WT littermates
Analysis at 6 months
On one-way ANOVA there was a difference between
groups in BrdU-positive cells in the dentate gyrus (DG)
(F = 12.90, P < 0.0001, Figure 7a). The Bonferroni post
hoc test showed that the DG of WT mice injected with
D-Ala2GIP contained significantly more BrdU-positive
cells than the other groups (P < 0.001). However, on
one-way ANOVA there was no difference between
groups in the number of double-cortin-positive young
neurons (F = 1.49, P > 0.05) (Figure 7b).
Analysis at 12 months
On one-way ANOVA there was no difference between
groups in BrdU-positive cells in the DG at 12 months
of age (F = 0.07, P > 0.05, Figure 8a). Moreover, there
was no difference between groups in the number of
double-cortin-positive young neurons (F = 2.11, P >
0.05) (Figure 8b).
Effect of D-Ala2GIP treatment on synaptic density of
APP/PS1 mice and WT littermates
Analysis at 6 months
On one-way ANOVA there was a difference between
groups in levels of expression of synaptophysin in the
exterior cortex (layers 4 to 6) (F = 6.62, P < 0.0001)
(Figure 9a) and interior cortex (layers 1 to 3) (F = 5.72,
P < 0.01). The Bonferonni post hoc test showed that D-
Ala2GIP treatment increased levels of synaptophysin in
the interior cortex in APP/PS1 mice compared with the
saline-treated APP/PS1 (P < 0.01), and in the exterior
cortex compared with both saline-treated APP/PS1 and
WT mice (P < 0.01).
On one-way ANOVA there was a difference between
groups in levels of expression of synaptophysin in the
polymorphic layer (hilus) of the DG (F = 4.95, P < 0.01),
the molecular layer of the DG (F = 3.55, P < 0.05) and
the stratum pyramidale (CA1) (F = 9.14, P < 0.0001).
A decrease in synaptophysin levels was found in APP/
PS1 mice compared to the WT control group in the
polymorphic layer (hilus) (P < 0.05), and a decrease was
found in the stratum pyramidale in the saline group
(P < 0.001) and in the D-Ala2GIP group (P < 0.05).
D-Ala2GIP treatment increased levels of synaptophysin
in APP/PS1 mice compared with the saline-treated
APP/PS1 mice in the polymorphic layer of the DG (P <
0.01), as well as in the molecular layer of the DG (P <
0.05). However, D-Ala2GIP treatment did not change
synaptophysin expression in WT and APP/PS1 mice in
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Figure 7 Histological analysis of biomarkers in the brain. Top half of Figure: effect of D-Ala2 glucose-dependent insulinotropic polypeptide
(GIP) treatment on cell proliferation of 6-month-old APP/PS1 mice and wild type (WT) littermates. Quantification of (A) BrdU-positive cells in the
dentate gyrus (DG0 of APP/PS1 and WT mice. Data show mean ± standard error of the mean (SEM) of six mice per group (one-way analysis of
variance, ANOVA, ***P < 0.001). The micrographs show examples of the DG of WT mice injected with (B) saline and (C) D-Ala2GIP, and APP/PS1
mice injected with (D) saline and (E) D-Ala2GIP peptide, immunohistologically stained against BrdU (scale bar: 210 μm). Bottom half of Figure:
effect of D-Ala2GIP treatment on neurogenesis of 6-month-old APP/PS1 mice and WT littermates. Quantification of (A) DCX-positive cells in the
DG of APP/PS1 and WT mice. Data show mean ± SEM of six mice per group (one-way ANOVA). The micrographs illustrate examples of the DG
of WT mice injected with (B) saline and (C) D-Ala2GIP, and APP/PS1 mice injected with (D) saline and (E) D-Ala2GIP peptide,
immunohistologically stained against DCX (scale bar: 210 μm).
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Figure 8 Histological analysis of biomarkers in the brain. Top half of Figure: effect of D-Ala2 glucose-dependent insulinotropic polypeptide
(GIP) treatment on cell proliferation of 12-month-old APP/PS1 mice and wild type (WT) littermates. Quantification of (A) BrdU-positive cells in
the dentate gyrus (DG) of APP/PS1 and WT mice. Data show mean ± standard error of the mean (SEM) of six mice per group (one-way analysis
of variance, ANOVA). The micrographs illustrate examples of the DG of WT mice injected with (B) saline and (C) D-Ala2GIP, and APP/PS1 mice
injected with (D) saline and (E) D-Ala2GIP peptide, immunohistologically stained against BrdU (scale bar: 210 μm). Bottom half of Figure: effect of
D-Ala2GIP treatment on neurogenesis of 12-month-old APP/PS1 mice and WT littermates. Quantification of (A) doublecortin (DCX)-positive cells
in the DG of APP/PS1 and WT mice. Data show mean ± SEM of 6 mice per group (one-way ANOVA). The micrographs illustrate examples of the
DG of WT mice injected with (B) saline and (C) D-Ala2GIP, and APP/PS1 mice injected with (D) saline and (E) D-Ala2GIP peptide,
immunohistologically stained against DCX (scale bar: 210 μm).
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Figure 9 Histological analysis of biomarkers in the brain. Top half of Figure: effect of D-Ala2 glucose-dependent insulinotropic polypeptide
(GIP) treatment on synaptic density on 6-month-old APP/PS1 mice and wild type (WT) age-matched littermates. Quantification of levels of
expression of synaptophysin in (A) the exterior neocortex (layers 1 to 3), and (B) the interior neocortex (layers 4 to 6). Data show mean ±
standard error of the mean (SEM) of six mice per group (one-way analysis of variance, ANOVA, **P < 0.01). Quantification of levels of expression
of synaptophysin in (C) the polymorphic layer of the dentate gyrus (DG), (D) the granular cell layer of the DG, (E) the molecular layer of the DG,
(F) the stratum radiatum, (G) the stratum pyramidal and (H) the stratum oriens. Data show mean ± SEM of six mice per group (one-way ANOVA,
* P < 0.05; ** P < 0.01; *** P < 0.001). Representative images of synaptophysin stained-brains of WT mice (scale bar: 440 μm). The photographs
on the top row show the polymorphic layer of the DG (a), the granular cell layer of the DG (b), the molecular layer of the DG (c), the stratum
radiatum (d), the stratum pyramidal (e) and the stratum oriens (f). On the micrograph, interior neocortex (g) and exterior neocortex (h) stained
against synaptophysin is shown. Bottom half of Figure: effect of D-Ala2GIP treatment on synaptic density on 12-month-old APP/PS1 mice and
WT age-matched littermates. Quantification of levels of expression of synaptophysin in (A) the exterior cortex, and (B) the interior cortex. Data
show mean ± SEM of six mice per group (one-way ANOVA). Hippocampus: (C) the polymorphic layer of the DG, (D) the granular cell layer of
the DG, (E) the molecular layer of the DG, (F) the stratum radiatum, (G) the stratum pyramidal and (H) the stratum oriens. Data show mean ±
SEM of six mice per group (one-way ANOVA). * P < 0.05; **P < 0.01; ***P < 0.001.
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the granular cell layer of the DG (F = 2.65, P > 0.05), in
the stratum radiatum (F = 2.15, P > 0.05), or the stra-
tum oriens (F = 1.24, P > 0.05). See Figure 9a.
Analysis at 12 months
On one-way ANOVA there was a difference between
groups in levels of expression of synaptophysin in the
exterior cortex (layers 406) (F = 10.52, P < 0.0001) and
interior cortex (layers 1 to 3) (F = 6.84, P < 0.0001).
The Bonferonni post hoc test showed a decrease of
synaptophysin expression in the 12 month-old APP/PS1
mice compared to their respective WT control in the
exterior cortex (P < 0.001 and P < 0.05). In the interior
cortex, APP/PS1 mice treated with saline exhibited
lower levels of synaptophysin expression than the WT
group (P < 0.001 compared to the saline group, and P <
0.01 compared to the D-Ala2GIP group), while D-Ala2-
GIP treatment increased levels of synaptophysin expres-
sion in APP/PS1 mice compared with the saline-treated
APP/PS1 (P < 0.05).
On one-way ANOVA there was a difference between
groups in levels of expression of synaptophysin in the
molecular layer of the DG (F = 8.71, P < 0.0001), the
stratum radiatum (F = 9.39, P < 0.0001), the stratum
pyramidale (F = 15.45, P < 0.0001), and the stratum
oriens (F = 5.88, P < 0.01) in area CA1. A decrease in
synaptophysin levels was found in saline-treated APP/
PS1 mice compared to the saline-treated WT control
group in the molecular layer and the stratum radiatum
(P < 0.01) and the stratum pyramidal (P < 0.001). More-
over, a decrease of synaptophysin levels was also found
in D-Ala2GIP-treated APP/PS1 mice compared to the
D-Ala2GIP-treated WT control group in the stratum
pyramidal (P < 0.01). However, D-Ala2GIP treatment
increased levels of synaptophysin in APP/PS1 mice in
the molecular layer of the DG (P < 0.05), in the stratum
radiatum and stratum pyramidal (P < 0.01), as well as in
the stratum oriens (P < 0.001). No change was detected
in the polymorphic layer (hilus) (F = 0.76, P > 0.05) and
in the granular cell layer of the DG (F = 1.97 P > 0.05)
of WT and APP/PS1 mice. See Figure 9b.
Effect of D-Ala2GIP treatment on plaque formation and
inflammation in the cortex of APP/PS1 mice
Analysis at 6 months
There was no difference between APP/PS1 mice injected
with saline or D-Ala2GIP in the number of plaques in
the cortex (t = 0.21, P > 0.05, Student’s unpaired t-test).
Additionally, D-Ala2GIP peptides showed no effect on
the amount of stained area for Congo red (t = 1.30, P >
0.05). However, a slight decrease in activated microglia
was found in the cortex of APP/PS1 mice treated with
D-Ala2GIP compared to the saline group (t = 2.00, P <
0.05) (Figure 10a).
Analysis at 12 months
There was a significant decrease in the number of pla-
ques (t = 2.41, P < 0.01) and a lower amount of Congo
red stained area (t = 1.96, P > 0.05, Student’s unpaired
t-test) in the cortex of 12 month-old APP/PS1 mice that
were chronically treated with D-Ala2GIP. Moreover, a
marked decreased in the inflammation response shown
in activated microglia was found in the cortex of D-
Ala2GIP-treated mice (t = 3.89, P < 0.001) (Figure 10b).
Discussion
The current study provides for the first time evidence
that chronic administration of D-Ala2GIP can improve
cognitive function in WT mice and prevent deficits of
learning and memory in APP/PS1 transgenic mice. Body
weight, blood glucose and plasma insulin levels were
monitored to demonstrate that this drug that had ori-
ginally had been developed as a treatment for type 2
diabetes does not affect these parameters. Changes in
blood glucose and insulin levels would be undesirable
and can lead to a deficit in cognitive performance
[44,51,52]. APP/PS1 mice had higher body weight at 6
and 12 months old compared to their WT age-matched
littermates. At 12 months of age, all mice had a decrease
in body weight, which could be the effect of regular
exercise during behavioural tasks, increasing energy
expenditure and reducing body weight. Higher glucose
levels were also found in the APP/PS1 mice at 6 and 12
months old when compared with the WT mice. How-
ever, blood glucose levels stayed in a normal range
(between 4 and 8 mM/l). Importantly, D-Ala2GIP treat-
ment did not affect body weight, blood glucose levels
and plasma insulin levels in either APP/PS1 or WT
mice at either of the ages tested. Another important
parameter to evaluate was the effect of D-Ala2GIP treat-
ment on the spontaneous behaviour of the transgenic
mouse, as a disturbance in locomotor activity, speed or
anxiety levels could affect the learning and memory in
some behavioural tasks. D-Ala2GIP treatment did not
alter locomotor activity measured as path length and
number of lines crossed, exploratory levels estimated by
the number of rearing events and speed in both trans-
genic and APP/PS1 mice in all different ages tested.
Anxiety levels were assessed by the number of grooming
events and the time spent in the centre of the open-field
test vs the periphery. Treatment with D-Ala2GIP pep-
tides did not affect the anxiety level of mice. Moreover,
spontaneous behaviour was not modified in the open-
field task. The same results were found for speed during
the acquisition trials in the MWM task. There was also
no effect on spontaneous behaviour found previously in
C57Bl/6J mice chronically injected with 25 nmol/kg D-
Ala2GIP for at least 21 days [43].
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Figure 10 Histological analysis of biomarkers in the brain. Top half of figure: effect of D-Ala2 glucose-dependent insulinotropic polypeptide
(GIP) treatment on three hallmarks of Alzheimer’s disease in 6-month-old APP/PS1 mice. (A) Quantification of beta-amyloid plaque, (B) of dense
core plaque load in the cortex of APP/PS1 and, (C) of activated microglia (neuroinflammation) in the cortex of APP/PS1 mice. The percentage of
stained cortex area was used as measurement for these three hallmarks. Data show mean ± standard error of the mean (SEM) of six mice per
group (Student’s unpaired t-test, *P < 0.05). Micrographs: The figures on the top row illustrate examples of the cortex of APP/PS1 mice injected
with (D) saline and (E) D-Ala2GIP, immunohistologically stained against b-amyloid (scale bar: 880 μm). The figures in the middle row illustrate
example of cortex of APP/PS1 mice injected with (F) saline and (G) D-Ala2GIP, stained with Congo red (scale bar: 880 μm). The figures on the
bottom row illustrate examples of cortex of APP/PS1 mice injected with (H) saline and (I) D-Ala2GIP, immunohistologically stained against Iba1
(scale bar: 80 μm). Bottom half of Figure: effect of D-Ala2GIP treatment on three hallmarks of Alzheimer’s disease in 12-month-old APP/PS1 mice.
(A) Quantification of beta-amyloid plaque, (B) of dense core plaque load in the cortex of APP/PS1 and, (C) of activated microglia
(neuroinflammation) in the cortex of APP/PS1 mice. The percentage of stained cortex area was used as measurement for these three hallmarks.
Data show mean ± SEM of six mice per group (Student’s unpaired t-test, *P < 0.05; **P < 0.01; ***P < 0.001). Micrographs: the figures on the top
row illustrate examples of the cortex of APP/PS1 mice injected with (D) saline and (E) D-Ala2GIP, immunohistologically stained against b-amyloid
(scale bar: 880 μm). The figures in the middle row illustrate example of cortex of APP/PS1 injected with (F) saline and (G) D-Ala2GIP, stained with
Congo red (scale bar: 880 μm). The figures on the bottom row illustrate example of cortex of APP/PS1 mice injected with (H) saline and (I) D-
Ala2GIP, immunohistologically stained against Iba1 (scale bar: 80 μm).
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In the ORT, mice spent more time exploring a novel
object than a previously explored object if the memory
of the familiar object was still intact [53,54]. Our results
show that object recognition memory was intact in
6-month-old WT and APP/PS1 mice. At 12 months of
age, saline-treated APP/PS1 mice failed to investigate
the novel object in the ORT, and treatment with the
D-Ala2GIP peptide rescued the memory deficit. The
WT group showed intact recognition memory when
tested at 12 months. In the water maze task at the age
of 6 months, all mice learned the task, also in a reversal
task where the platform was moved to another location.
This task requires re-learning of the location and repres-
sion of the previous memory. This task is often harder
to learn for animals that are impaired in learning [55].
At 12 months of age, all mice learned the acquisition
and reversal task, and the saline-treated APP/PS1 group
performed similar to WT mice injected with saline dur-
ing the acquisition task. Importantly, both the WT and
APP/PS1 group injected with D-Ala2GIP learned the
location of the hidden escape platform faster than the
saline groups. However, APP/PS1 mice displayed
impaired spatial reference memory during the probe
trial and reversal probe trial, as mice spent an equal
amount of time in each quadrant of the pool. It seems
that the 12 month-old APP/PS1 group was still able to
acquire the task, but was unable to memorise and recall
the exact spatial location using distal cues as the WT
group did. Furthermore, WT control mice exhibited a
deficit in spatial memory during the reversal probe trial.
This decreased selectivity for the target quadrant in
aged WT mice shows impairment in re-learning the
new location of the platform. However, all mice treated
with D-Ala2GIP showed an intact spatial memory in
both recall tasks for the APP/PS1 and WT group,
demonstrating the effectiveness of this drug.
Synaptic degeneration has been found in the brains of
AD patients, which may be the underlying cause of
memory impairment [56,57]. Thus, we examined the
effect of chronic treatment of D-Ala2GIP on levels of
the synaptic marker synaptophysin in the different layers
of the hippocampus and the cortex of APP/PS1 and WT
mice. Synaptic numbers in the brains of APP/PS1 mice
were reduced. At 6 months, levels of synaptophysin
were lower in the stratum pyramidale and polymorphic
layer of the DG of APP/PS1 mice. A general decrease in
synapse numbers was found in the cortex and in most
of the layers of the DG in APP/PS1 mice at 12 months.
This loss can explain the cognitive impairment of APP/
PS1 observed during the ORT and the water maze task.
Importantly, the synaptic degeneration was rescued by
the D-Ala2GIP treatment. The 6-month-old APP/PS1
group treated with D-Ala2GIP displayed similar levels of
synaptophysin in the polymorphic layer of the DG as in
the WT group control. The deterioration of synapses in
the interior cortex and in some layers of the hipppocam-
pus of APP/PS1 was also prevented by administration
of D-Ala2GIP in the 12-month-old group. Moreover,
D-Ala2GIP increased the number of synapses in the cor-
tex and the molecular layer of the DG of APP/PS1 mice
at 6 months. Thus, the synaptic increase in the brains of
WT mice treated with D-Ala2GIP could have led to the
cognitive improvement. Moreover, as the reduction in
the number of synapses was lower in the D-Ala2GIP-
treated APP/PS1 mice, D-Ala2GIP protects synapses and
rescues cognitive deficits found in the APP/PS1 mice.
We have previously shown that GIPRs play an important
role in synaptic plasticity, as LTP was obliterated in the
GIPR knockout (KO) mice [47], and activation of GIPRs
in the hippocampus by the GIP agonist N-AcGIP
enhanced the induction of LTP [38]. Thus, we assessed
the effect of D-Ala2GIP on synaptic function of APP/PS1
and WT littermates. In this study, different aspects of
in vivo synaptic function were evaluated, such as basic
neurotransmission, LTP and gamma amino butyric acid
(GABA)-ergic inhibition in area CA1 using PPF. At the
ages that have been investigated, comparison of post-HFS
slopes of fEPSPs revealed an increase in the D-Ala2GIP
treatment group. Thus, chronic administration of D-Ala2-
GIP facilitated LTP induction and expression in APP/PS1
mice at 6 and 12 months of age, as well as their WT age-
matched littermates. The LTP facilitation in the D-Ala2-
GIP-treatment group could be the result of an enhance-
ment in the post-synaptic LTP induction mechanism, an
increase of presynaptic transmitter release, or a change in
local inhibition in the CA1 region of the hippocampus. In
addition, an increased number of synapses can be the rea-
son for enhanced LTP. The synaptophysin study showed
that D-Ala2GIP increased the number of synapses, either
by protecting them from elimination or by direct synapto-
genesis. Pre-synaptic functions and inter-neuronal activity
were assessed by PPF measurements. The PPF induced at
short inter-stimulus intervals is considered to be triggered
by pre-synaptic transmitter release facilitating processes
[58], while later PPF is considered to be linked to GABAA
and GABAB inter-neuronal synaptic transmission [59-61].
Even though an overall increase in PPF was found for the
APP/PS1 group injected with D-Ala2GIP at 6 months of
age, no difference in the specific inter-stimulus interval
parameters has been shown. Thus, D-Ala2GIP does not
increase vesicle release and does not seem to change the
local inhibition in the CA1 region of the hippocampus,
suggesting that synaptogenesis is the main factor in the
enhancement of LTP.
The effects of D-Ala2GIP on the classic hallmarks of
AD were investigated in the cortex of APP/PS1 mice.
Treatment of D-Ala2GIP reduced the number of beta-
amyloid plaques in APP/PS1 mice at 12 months of age.
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Moreover, the overall number of dense-core Congo red-
positive plaques was reduced at 12 months. Clearly, the
removal of plaques in the brain is a very desirable result,
as aggregated amyloid can trigger an inflammatory
response [62]. Increasingly, the role of amyloid oligo-
mers has been brought into the focus of research. There
is evidence to suggest that such soluble oligomers have
neurotoxic effects [63]. It would be of interest to analyse
levels of different species of oligomers in the brains of
drug-treated APP/PS1 mice.
Importantly, D-Ala2GIP-treatment decreased the level
of the activated microglia marker Iba1 in the cortex of
APP/PS1 mice, showing that the neuroinflammation
response was decreased by D-Ala2GIP-treatment.
Chronic inflammation is one of the hallmarks of AD [64].
Abnormal production of pro-inflammatory cytokines by
activated microglia can interrupt nerve terminal activity,
leading to synapse dysfunction and loss, which correlates
with cognitive decline [65-67]. Thus, the protective effect
of D-Ala2GIP on synapses could derive from a decrease
of neuroinflammation in the brain of APP/PS1 mice.
It has been shown that GIP induces progenitor cell
proliferation [35] and in contrast, the lack of GIPRs in
KO mice affects cell proliferation in the hippocampus
[47]. In this study, chronic administration of D-Ala2GIP
significantly increased the number of BrdU-positive cells
in the DG of WT mice at 6 months of age. This observa-
tion that DAla2GIP enhanced neuronal progenitor prolif-
eration in the brain, which has been previously found
[35], is also of great importance, as the increase of such
cells could be of use for repairing neuronal damage [68].
However, this beneficial effect was not observed in the
APP/PS1 mice at 12 months old. We also tested the
number of immature neurons as identified by DCX, a cell
marker for immature neurons. D-Ala2GIP did not affect
the number of DCX-positive cells in the DG of APP/PS1
mice or their WT littermates. Thus, D-Ala2GIP does not
seem to play a role in neuronal cell differentiation. This
finding confirms the previous finding that a lack of the
GIPR did not affect the level of immature neurons in the
DG of GIPR KO mice [47].
The data presented here have been extended in a sepa-
rate study on the effects of D-Ala2GIP on 19-month-old
APP/PS1 mice. It was found that in the very old groups,
D-Ala2GIP still had some protective effects and reduced
the plaque load, the inflammatory response (Iba1 stain)
and also protected LTP from degeneration [69]. This
shows that the drug has some beneficial effects even in
the advanced stages of degeneration. In an additional
study of the brains of these 6-, 12- or 19-month-old
mice, it was found that D-Ala2GIP treated APP/PS1 mice
had much reduced oxidative stress (8-oxoguanine levels)
and astrogliosis in the brain [70].
Conclusions
In conclusion, the results of chronic administration of D-
Ala2GIP demonstrate that GIP analogues have a range of
properties that may be beneficial in treating neurodegen-
erative conditions such as AD. It our study, D-Ala2GIP
induced synaptogenesis and protected synapses, which
led to cognitive improvement in WT mice and prevented
memory decline in APP/PS1 mice. It has been found that
GIP also promotes axonal growth after nerve crush [40].
This growth factor-like property can be of use in neuro-
protection and neuroregeneration in AD. Moreover,
D-Ala2GIP facilitated LTP, highlighting the important
role of the GIPR in synaptic plasticity and confirming
that synapses were not only protected from degradation
in the APP/PS1 mice, but were fully functional. Impor-
tantly, D-Ala2GIP decreased the number of amyloid pla-
ques and neuroinflammation in the cortex of transgenic
mice. This is of great interest, as neurotoxic effects asso-
ciated with plaques and inflammation are considered one
of the important underlying mechanisms of neurodegen-
eration found in AD [71,72]. The beneficial actions of
GIP suggest that the use of long-lasting analogues may
be an attractive therapeutic approach for the treatment
of neurodegenerative diseases such as AD. One possible
mechanism of action is the re-sensitisation of insulin sig-
naling, or the compensation of insulin de-sensitisation by
GIPR activation. Further research in mouse models of
neurodegenerative diseases will be required to under-
stand mechanisms that underlie the neuroprotective
properties of GIP analogues.
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